Genetics, autoantibodies and clinical features in understanding and
predicting rheumatoid arthritis
Helm-van Mil, A.H.M. van der
Citation
Helm-van Mil, A. H. M. van der. (2006, October 26). Genetics, autoantibodies and clinical
features in understanding and predicting rheumatoid arthritis. Retrieved from
https://hdl.handle.net/1887/4929
Version:
Corrected Publisher’s Version
License:
Licence agreement concerning inclusion of doctoral thesis in the
Institutional Repository of the University of Leiden
Downloaded from:
https://hdl.handle.net/1887/4929
!NTI ##0¬ANTIBODIES¬AND¬CLINICAL¬CHARACTERISTICS¬IN¬2!
).42/$5#4)/.
!UTOANTIBODIES¬ DIRECTED¬ TO¬ CITRULLINATED¬ PROTEINS¬ EG¬ ANTI CYCLIC CITRULLINATED¬ PEPTIDE ¬ ANTI ##0¬ANTIBODIES ¬ARE¬HIGHLY¬SPECIl¬C¬SEROLOGICAL¬MARKERS¬FOR¬RHEUMATOID¬ARTHRITIS¬2! ¬ THAT¬ARE¬THOUGHT¬TO¬BE¬DIRECTLY¬INVOLVED¬IN¬THE¬DISEASE¬PATHOGENESIS¬ ¬#ITRULLINATED¬PRO TEINS¬ARE¬NOT¬EXCLUSIVELY¬LOCATED¬IN¬SYNOVIAL¬TISSUE¬OF¬2!¬PATIENTS ¬BUT¬CAN¬ALSO¬BE¬FOUND¬IN SYNOVIUM¬SAMPLES¬OF¬PATIENTS¬WITH¬OTHER¬INm¬AMMATORY¬JOINT¬DISEASES¬ ¬SUGGESTING¬THAT THE¬SPECIl¬CITY¬OF¬ANTI ##0¬ANTIBODIES¬FOR¬2!¬IS¬NOT¬DUE¬TO¬THE¬EXPRESSION¬OF¬CITRULLINATED¬ PROTEINS¬BUT¬MIGHT¬BE¬THE¬RESULT¬OF¬AN¬ABNORMAL¬HUMORAL¬RESPONSE¬)NTRIGUINGLY¬THIS¬ANTI BODY¬RESPONSE¬MAY¬OCCUR¬YEARS¬BEFORE¬ANY¬CLINICAL¬SYMPTOMS ¬AS¬SHOWN¬BY¬THE¬PRESENCE¬OF¬ ANTI ##0¬ANTIBODIES¬SEVERAL¬YEARS¬BEFORE¬THE¬CLINICAL¬ONSET¬OF¬ARTHRITIS¬ ¬&URTHERMORE A¬PROPORTION¬OF¬2!¬PATIENTS¬DO¬NOT¬HARBOUR¬ANTI ##0¬ANTIBODIES ¬SUGGESTING¬THAT¬THE¬PRES ENCE¬OF¬ANTI ##0¬ANTIBODIES¬IS¬NOT¬OBLIGATORY¬FOR¬THE¬DEVELOPMENT¬OF¬ARTHRITIS¬OR¬THAT¬THE¬ PATHOGENIC¬MECHANISMS¬UNDERLYING¬ANTI ##0¬POSITIVE¬AND¬NEGATIVE¬2!¬ARE¬DIFFERENT 4HESE¬OBSERVATIONS¬INSPIRED¬SUBSEQUENT¬RESEARCH¬ADDRESSING¬THE¬QUESTION¬WHETHER¬2!¬PA TIENTS¬WITH¬ANTI ##0¬ANTIBODIES¬ARE¬DIFFERENT¬FROM¬THOSE¬WHO¬ARE¬ANTI ##0¬NEGATIVE¬6ERY RECENTLY ¬ WE¬ DEMONSTRATED¬ IN¬ TWO¬ INDEPENDENT¬ #AUCASIAN¬ POPULATIONS¬ THAT¬ THE¬ SHARED¬ EPITOPE¬ENCODING¬(,! $"2¬ALLELES¬ASSOCIATE¬WITH¬2!¬IN¬PATIENTS¬WITH¬ANTI ##0¬ANTIBOD IES¬BUT¬NOT¬IN¬PATIENTS¬WITHOUT¬THESE¬ANTIBODIES¬UNPUBLISHED¬DATA ¬ ¬4HESE¬l¬NDINGS¬ARE¬ IMPORTANT¬AS¬THEY¬INDICATE¬THAT¬THE¬SHARED¬EPITOPE¬ALLELES¬ARE¬NOT¬ASSOCIATED¬WITH¬2!¬AS SUCH ¬BUT¬RATHER¬WITH¬A¬PARTICULAR¬PHENOTYPE¬OF¬THE¬DISEASE
#
HA
P
TER¬
!NTI ##0¬ANTIBODIES¬AND¬CLINICAL¬CHARACTERISTICS¬IN¬2!
!NTI ##0¬ANTIBODIES¬AND¬CLINICAL¬CHARACTERISTICS¬IN¬2!
# HA P TER¬ !CUTE¬PHASE¬REACTANT¬AT¬INITIAL¬PRESENTATION 4HE¬MEAN¬# REACTIVE¬PROTEIN¬LEVEL¬WAS¬¬MG,¬3$¬ ¬IN¬THE¬ANTI ##0¬NEGATIVE¬2! PATIENTS¬AND¬¬MG,¬3$¬ ¬IN¬THE¬ANTI ##0¬POSITIVE¬PATIENTS ¬AND¬WAS¬NOT¬SIGNIl¬ CANTLY¬DIFFERENT¬BETWEEN¬THE¬TWO¬GROUPS¬P 3WOLLEN¬JOINTS¬AT¬FOLLOW UP
!NTI ##0¬ANTIBODIES¬AND¬CLINICAL¬CHARACTERISTICS¬IN¬2!
#
HA
P
TER¬
MORE¬ DELAYED¬ TREATMENT¬ OF¬ THESE¬ PATIENTS¬ OR¬ CONFOUNDING¬ BY¬ TREATMENT¬ ADAPTED¬ TO¬ THE¬ ANTI ##0¬STATUS¬7E¬CANNOT¬EXCLUDE¬THAT¬DURING¬FOLLOW UP¬THE¬ANTI ##0¬POSITIVE¬PATIENTS¬ THAT¬HAD¬MORE¬INm¬AMED¬JOINTS¬RECEIVED¬MORE¬AGGRESSIVE¬TREATMENT¬(OWEVER ¬IN¬CASE¬OF¬ A¬MORE¬AGGRESSIVE¬TREATMENT¬DURING¬FOLLOW UP¬IN¬ANTI ##0¬POSITIVE¬PATIENTS ¬THIS¬DID¬NOT PREVENT¬THE¬DEVELOPMENT¬OF¬MORE¬SEVERE¬RADIOLOGICAL¬DESTRUCTION¬IN¬THE¬2!¬PATIENTS¬WITH ANTI ##0¬ANTIBODIES¬4HE¬l¬NDING¬THAT¬THE¬SWOLLEN¬JOINT¬COUNT¬DECREASED¬DURING¬FOLLOW UP¬ IS¬PROBABLY¬DUE¬TO¬THE¬FACT¬THAT¬AT¬INCLUSION¬PATIENTS¬WERE¬NOT¬TREATED¬WITH¬DISEASE¬MODIFY ING¬ANTIRHEUMATIC¬DRUGS 4HE¬SENSITIVITY¬OF¬ANTI ##0¬ANTIBODIES¬FOR¬2!¬IS¬REPORTED¬TO¬VARY¬BETWEEN¬¬AND¬ ¬4HE¬PRESENT¬STUDY¬MEASURED¬ANTI ##0¬LEVELS¬AT¬INCLUSION¬A¬VERY¬EARLY¬STAGE¬OF¬ THE¬DISEASE ¬AND¬REPORTS¬A¬RELATIVELY¬LOW¬PERCENTAGE¬ ¬OF¬2!¬PATIENTS¬WITH¬ANTI ##0¬ ANTIBODIES¬!S¬##0¬MEASUREMENTS¬WERE¬NOT¬REPEATED¬DURING¬FOLLOW UP ¬WE¬CANNOT¬EXCLUDE¬ THAT¬SOME¬2!¬PATIENTS¬THAT¬WERE¬ANTI ##0¬NEGATIVE¬AT¬INCLUSION¬HAVE¬BECOME¬ANTI ##0¬ POSITIVE¬ON¬A¬LATER¬STAGE¬IN¬THE¬DISEASE¬!¬RELATIVELY¬LOW¬PREVALENCE¬OF¬ANTI ##0¬ANTIBODIES IN¬EARLY¬ARTHRITIS¬PATIENTS¬HAS¬BEEN¬DESCRIBED¬BEFORE¬ 4HE¬PRESENT¬STUDY¬SHOWS¬THAT¬THE¬SECOND¬AND¬THIRD¬-#0¬JOINTS¬HAVE¬THE¬HIGHEST¬EROSION SCORES ¬AS¬WELL¬AS¬THE¬HIGHEST¬JOINT¬SPACE¬NARROWING¬SCORES¬AND¬ARE ¬OF¬ALL¬-#0¬JOINTS ¬MOST¬ FREQUENTLY¬SWOLLEN¬!LTHOUGH¬THE¬PRESENT¬STUDY¬WAS¬NOT¬DESIGNED¬TO¬STUDY¬THE¬CORRELATION BETWEEN¬INm¬AMMATION¬AND¬DESTRUCTION ¬THE¬OBSERVED¬SIMILARITY¬IN¬JOINTS¬THAT¬ARE¬AFFECTED BY¬SWELLING ¬EROSIONS¬AND¬JOINT¬SPACE¬NARROWING¬SUPPORTS¬THE¬CONCEPT¬THAT¬IN¬GENERAL¬THE¬ MECHANISMS¬LEADING¬TO¬CLINICAL¬INm¬AMMATION¬AND¬RADIOLOGICAL¬DESTRUCTION¬ARE¬RELATED¬ 4HIS¬STUDY¬INCLUDES¬A¬DETAILED¬DESCRIPTION¬ON¬THE¬DISTRIBUTION¬OF¬AFFECTED¬JOINTS¬IN¬2!¬AND SHOWS¬THAT¬THE¬-#0¬JOINTS¬OF¬THE¬SECOND¬AND¬THE¬THIRD¬DIGITS¬ARE¬MOST¬FREQUENTLY¬INm¬AMED AND¬DESTRUCTED¬!LTHOUGH¬TO¬OUR¬EXPERIENCE¬RHEUMATOLOGISTS¬GENERALLY¬FEEL¬THAT¬THE¬JOINTS¬ OF¬THE¬SECOND¬AND¬THIRD¬DIGITS¬ARE¬MORE¬FREQUENTLY¬INm¬AMED¬THAN¬OTHER¬JOINTS¬OF¬THE¬HANDS TO¬OUR¬KNOWLEDGE¬THIS¬PHENOTYPIC¬CHARACTERISATION¬HAS¬NOT¬BEEN¬FREQUENTLY¬DESCRIBED¬ #/.#,53)/.
!NTI ##0¬ANTIBODIES¬AND¬CLINICAL¬CHARACTERISTICS¬IN¬2! 2%&%2%.#%3 ¬ ¬ 6OSSENAAR¬%2 ¬:ENDMAN¬!* ¬6AN¬6ENROOIJ¬7*¬#ITRULLINATION ¬A¬POSSIBLE¬FUNCTIONAL¬LINK BETWEEN¬SUSCEPTIBILITY¬GENES¬AND¬RHEUMATOID¬ARTHRITIS¬!RTHRITIS¬2ES¬4HER¬ ¬ ¬ 6OSSENAAR¬%2 ¬3MEETS¬4* ¬+RAAN¬-# ¬2AATS¬*- ¬VAN¬6ENROOIJ¬7* ¬4AK¬00¬4HE¬PRESENCE¬ OF¬CITRULLINATED¬PROTEINS¬IS¬NOT¬SPECIl¬C¬FOR¬RHEUMATOID¬SYNOVIAL¬TISSUE¬!RTHRITIS¬2HEUM¬ ¬ ¬ 2ANTAPAA $AHLQVIST¬3 ¬DE¬*ONG¬"! ¬"ERGLIN¬% ¬(ALLMANS¬' ¬7ADELL¬' ¬3TENLUND¬( ¬3UNDIN 5 ¬VAN¬6ENROOIJ¬7*¬!NTIBODIES¬AGAINST¬CYCLIC¬CITRULLINATED¬PEPTIDE¬AND¬)G!¬RHEUMATOID¬ FACTOR¬PREDICT¬THE¬DEVELOPMENT¬OF¬RHEUMATOID¬ARTHRITIS¬!RTHRITIS¬2HEUM¬ ¬ ¬ .IELEN¬-- ¬VAN¬3CHAARDENBURG¬$ ¬2EESINK¬(7 ¬VAN¬DE¬3TADT¬2* ¬VAN¬DER¬(ORST "RUINSMA¬ )% ¬DE¬+ONING¬-( ¬(ABIBUW¬-2 ¬6ANDENBROUCKE¬*0 ¬$IJKMANS¬"!#¬3PECIl¬C¬AUTOANTI BODIES¬PRECEDE¬THE¬SYMPTOMS¬OF¬RHEUMATOID¬ARTHRITIS¬A¬STUDY¬OF¬SERIAL¬MEASUREMENTS¬IN BLOOD¬DONORS¬!RTHRITIS¬2HEUM¬ ¬ ¬ 6AN¬'AALEN¬&! ¬VAN¬!KEN¬* ¬(UIZINGA¬47 ¬3CHREUDER¬'- ¬"REEDVELD¬&# ¬:ANELLI¬% ¬VAN¬ 6ENROOIJ¬7* ¬6ERWEIJ¬#, ¬4OES¬2%- ¬DE¬6RIES¬220¬!SSOCIATION¬BETWEEN¬(,!¬CLASS¬))¬GENES¬ AND¬ AUTOANTIBODIES¬ TO¬ CYCLIC¬ CITRULLINATED¬ PEPTIDES¬ ##0S ¬ INm¬UENCES¬ THE¬ SEVERITY¬ OF¬ RHEUMATOID¬ARTHRITIS¬!RTHRITIS¬2HEUM¬ ¬ ¬ &ORSLIND¬+ ¬!HLMEN¬- ¬%BERHARDT¬+ ¬(AFSTROM¬) ¬3VENSSON¬"¬"!2&/4¬3TUDY¬'ROUP¬0RE DICTION¬OF¬RADIOLOGICAL¬OUTCOME¬IN¬EARLY¬RHEUMATOID¬ARTHRITIS¬IN¬CLINICAL¬PRACTICE¬ROLE¬OF¬ ANTIBODIES¬TO¬CITRULLINATED¬PEPTIDES¬ANTI ##0 ¬!NN¬2HEUM¬$IS¬ ¬ ¬ !KEN¬* ¬"ILSEN¬*!- ¬!LLAART¬#& ¬(UIZINGA¬47* ¬"REEDVELD¬&#¬4HE¬,EIDEN¬%ARLY¬!RTHRITIS #LINIC¬#LIN¬%XP¬2HEUMATOL¬3UPPL¬ 3 ¬ ¬ 6AN¬2IEL¬0, ¬VAN¬'ESTEL¬!- ¬3COTT¬$'¬)N¬%5,!2¬HANDBOOK¬OF¬CLINICAL¬ASSESSMENTS¬IN¬ RHEUMATOID¬ARTHRITIS¬!LPHEN¬AAN¬DEN¬2IJN ¬4HE¬.ETHERLANDS¬6AN¬:UIDEN¬#OMMUNICA TIONS¬ ¬
